Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of ibrutinib
alone or in combination with either cytarabine or azacitidine in the treatment of subjects
with Acute Myeloid Leukemia (AML) who have failed standard treatment, or subjects without
prior therapy who refuse standard chemotherapy.